Clinical Trial Update: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing bempedoic acid added to ezetimibe for lowering LDL-C in patients with hypercholesterolemia/atherosclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Hypercholesterolemia

Drugs mentioned

• Bempedoic Acid (bempedoic acid)
• EZETIMIBE (EZETIMIBE)

Snippet

Sponsor: Esperion Therapeutics, Inc. | Conditions: Hypercholesterolemia, Atherosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2020-04-03